To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
5 Current news of Takara Biorss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Clontech owner demonstrates confidence in European research market by establishing wholly-owned sales organisation
Takara Bio Europe announced that it will start selling its range of Takara brand products exclusively and directly to customers in the UK, Germany, Austria and Switzerland, with immediate effect. The decision means customers will be able to buy both Takara and Clontech brand products from one ...
MDxHealth SA announced that it has granted a non-exclusive worldwide license for its patented methylation specific PCR (MSP) technology to Takara Bio Inc.. Under the agreement, Takara Bio Inc. (Takara) has licensed the use of MDxHealth's MSP technology, the most widely applied methylation ...
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and TET Systems, a privately-held German biotech company based in Heidelberg, announced that they have signed an amendment to their existing license agreement. Under the expanded license agreement, Clontech obtains rights ...
Takara Bio Inc. announced that it has entered into a definitive agreement to acquire the Clontech unit ("Clontech") of BD Biosciences, mainly consisting of Clontech Laboratories Inc. (employees: 190), for USD $60 million (adjusted from USD $65 million due to the retention of certain inventories ...
Takara Bio Inc. agreed on August 31, 2004 to undertake clinical development of cancer immunotherapy intended for commercialization jointly with Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing. Presently, in China, too, malignant tumor is the leading cause of death, ...